ISTH 2022 – Sanofi faces more fitusiran doubts
An investigator asks whether the haemophilia project, which has already been linked with toxicity concerns, should be given to elderly patients.
ICNMD 2022 – still unclear whether Sarepta can accelerate
New data with SRP-9001 look decent, but filing plans remain uncertain.
The mystery of Jemperli’s rectal cancer breakthrough
If Jemperli might effectively cure a biomarker-defined subset of rectal cancer patients why isn't pharma more interested?
EHA 2022 – Crispr still looks bloody good
Updated data with exa-cel in sickle cell disease and beta-thalassaemia could put the fear into competitors.
EHA 2022 – Caribou’s turn to run into allo Car-T relapses
The recently listed company’s investors get déjà vu with the first human data from a trial of the allogeneic cell therapy CB-010.
